Biomarker endpoint assessment for clinical outcomes in acute kidney injury

Biomarker endpoint assessment for clinical outcomes in acute kidney injury - BEACON-AKI

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038863

Enrollment

400

Registered

2026-01-02

Start date

2026-01-02

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N17.8

Interventions

Group 1: Patients who have undergone major surgery are included in the study postoperatively if certain risk factors are present, and biological samples (blood and urine) are taken. If these patients

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Major surgery (cardiac surgery, abdominal surgery, and vascular surgery) with a duration of > 2h - Planned admission to the Intensive Care Unit, Intermediate Care or PACU after surgery - One of the following Risk factors: a. Age >70 years b. Use of catecholamines c. CKD d. Mechanical ventilated - Written informed consent

Exclusion criteria

Exclusion criteria: - Pre-existing AKI - Kidney transplantation within the last 12 Months - End stage renal disease with dialysis dependency - COPD requiring permanent oxygen therapy - Alzheimer disease or dementia of any kind - High doses of corticosteroids (cutoff: Prednisolone (7,5 mg) or hydrocortisone (>3 mg form men, > 20 mg for women) ) - Any form of dependency to the investigators

Design outcomes

Primary

Measure	Time frame
The primary objective of this trial is to determine whether patients with higher grade (grade 2-3) AKI have more AKI-associated complications than patients with lower grade (grade 1) or no AKI. •AKI-related complications during AKI stay; composite endpoint consisting of a.Cardiac arrhythmias – new onset of atrial fibrillation b.Delirium c.new onset of infection (infection with proved pathogen and increase of clinical infection marker (e.g. leukocytes, CRP, PCT) and the prescription of antibiotics) d.prolonged mechanical ventilation (longer than 12 hours) e.post-operative bleeding, defined as a blood loss that requires blood transfusion	—

Measure

Time frame

The primary objective of this trial is to determine whether patients with higher grade (grade 2-3) AKI have more AKI-associated complications than patients with lower grade (grade 1) or no AKI. •AKI-related complications during AKI stay; composite endpoint consisting of a.Cardiac arrhythmias – new onset of atrial fibrillation b.Delirium c.new onset of infection (infection with proved pathogen and increase of clinical infection marker (e.g. leukocytes, CRP, PCT) and the prescription of antibiotics) d.prolonged mechanical ventilation (longer than 12 hours) e.post-operative bleeding, defined as a blood loss that requires blood transfusion

—

Secondary

Measure	Time frame
• Use of renal replacement therapy • Length of ICU stay • Length of hospital stay • Survival • ICU mortality • Hospital mortality • MAKE90 (major adverse kidney events at day 90): combined endpoint consisting of: mortality, renal replacement therapy, and persistent renal dysfunction defined as serum-creatinine = 1.5 times as compared to baseline serum-creatinine	—

Countries

Germany

Contacts

Public ContactMoritz Mertes

Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie; Universitätsklinikum Münster

moritz.mertes@ukmuenster.de+49 251 83 47573

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026